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Retinopathy	 of	 prematurity	 (ROP),	 an	 ischemia‑induced	
retinopathy, is the most common ophthalmic condition linked 
with premature birth[1]	and	remains	a	significant	contributor	
to childhood blindness globally[2] and an incipient cause in 
developing nations.[3,4]
ROP	was	first	 termed	 retrolental	fibroplasia (RLF) in 1942 
by Terry.[5]	By	 the	 early	 1950s,	 hyperoxia	was	 implicated	
in the growing incidence of RLF. With a seemingly better 
knowledge	of	ROP	two	decades	later,	an	effort	at	treatment	was	
attempted.	However,	concerns	such	as	lack	of	an	appropriate	
classification	 system	made	 the	 results	 unimpressive.[6]	By	
1984,	the	publication	of	an	appropriate	classification	system[7] 
upgraded	the	management	of	ROP.
Routine screening of preterm babies was not the norm due to 
limitations or lack of screening facilities, skilled workforce, 
and nonavailability of treatment modalities.[8,9] Recent reports 
in various parts of Africa show an increasing trend in the 
screening	 and	 detection	 rate	 of	ROP.[10,11] Various studies 
carried out locally in Nigeria have also revealed increasing 
rates	 of	 screening	 and	diagnosis	 of	ROP.[12-14] Furthermore, 
increasing access to specialized neonatal care units and 
an upsurge in the uptake of assisted conception especially 
in vitro fertilization have been associated with preterm babies’ 
survival.	Some	of	the	documented	risk	factors	for	ROP	include	
prematurity which predisposes to conditions such as sepsis 
and respiratory distress, for which supplemental oxygen is 




at the periphery. Subsequently, as the infant grows, these undeveloped retinas lacking an adequate supply of oxygen then stimulate angiogenic 







the guidelines given in this study should be considered to minimize complications.
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Figure 1: Retinopathy of prematurity in Ibadan
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being diagnosed and treated [Figure 1].
The	current	treatment	modalities	for	ROP	are	dependent	on	
indications	for	treatment.	Type	1	ROP	is	treated	while	Type	
2 is observed closely.[15]	The	treatment	of	ROP	is	dependent	
on the stage or zone of presentation and may include retinal 
laser photocoagulation, injection of antivascular endothelial 
growth	 factor	 (anti‑VEGF)	 (bevacizumab/ranibizumab),	 or	
pars plana vitrectomy.[16-19]
Anti‑VEGF	 therapy	 for	 ROP	was	 primarily	 considered	
after earlier studies[20-22]	 recognized	VEGF	as	 an	 important	
mediator	in	the	vasoproliferative‑ROP‑pathway.	Furthermore,	
the superiority of bevacizumab over other treatment options 
was	 restated	by	 the	multicenter	 clinical	 trial;	Bevacizumab	
Eliminates the Angiogenic Threat of Retinopathy of 
Prematurity	(BEAT‑ROP).[23]
Modalities of treatment in our hospital, depending on the stage 
at diagnosis include intravitreal bevacizumab and retinal laser 
therapy. Our choice of bevacizumab is because it is much 
cheaper than ranibizumab and a single vial can be used for 
multiple injections under strict asepsis. It has been proven that 
bevacizumab	may	be	more	efficacious	 than	 ranibizumab	 in	
ROP	with	fewer	chances	of	recurrence	and	lower	probability	
of repeat intravitreal injections.[24]	The	BEAT‑ROP	 study	
showed	fewer	recurrences	of	posterior	ROP	with	intravitreal	
bevacizumab and also lesser complications when compared 
to laser therapy.[23]
An advantage of intravitreal bevacizumab is the fact that it 
is a brief procedure in comparison to laser photocoagulation 
and hence less stressful for the neonate. Due to the brevity 
of the procedure, it may be used to treat very ill babies 
who otherwise may not be able to withstand the stress of 
laser	 photocoagulation.	Other	 advantages	 of	 anti‑VEGF	
injections include its ability to avoid retina scars and scotomas 
associated with laser pan-retinal photocoagulation. Laser 
photocoagulation also induces the progression of myopia, 
which	is	not	seen	with	anti‑VEGF.[23]
Despite	 the	 benefits	 of	 anti‑VEGF,	 possible	 disadvantages	
include the possible development of endophthalmitis and 
retinal detachment.[25] Other reported adverse events are optic 
atrophy, retinal breaks, macula hole, and retinal pigment 
epithelial	(RPE)/choroidal	rupture.[26,27]
Though existing literature have reported low rate of 
complications,[28]	 infants	 receiving	 intravitreal	 anti‑VEGF	
should be followed up closely for prompt diagnosis of 
vision-threatening events.
Method of adMInIstRatIon of IntRavItReal 
antIvasculaR endothelIal gRowth factoR In a 
neonate wIth RetInoPathy of PReMatuRIty












•	 Zone	 III	 babies	 with	 type	 1	 ROP	 not	 fit	 for	 laser	
photocoagulation (hazy media).
Preoperative preparation
•	 Neonates	must	 have	 been	 certified	fit	 for	 intravitreal	
injection by managing neonatology team
•	 Preferable	to	give	the	intravitreal	injection	in	the	operating	
theater. Occasionally, it can be given in the neonatal unit, 





operating list when other patients are scheduled for 
anti‑VEGF	therapy.
Procedure
•	 The	neonatal	 team	must	certify	 the	neonate	fit	 for	 the	
injection by the absence of apnea and fever. The vital 
signs must be stable and continuously monitored with 
a pulse oximeter. The neonatal team including a doctor 
and nurse are always present to monitor the baby, while 
the injection is being administered in our center. Our 
operating	theater	is	on	the	same	floor	and	directly	opposite	
the neonatal ward, so providing easy access
•	 Neonates	 are	 positioned	 on	 the	 operating	 table	 and	
monitored by an assistant [Figure 2]
•	 A	small	headrest	or	doughnut	is	made	to	support	the	head
•	 Topical	 anesthesia	 with	 instillation	 of	 one	 drop	 of	
tetracaine hydrochloride every 5 min for 15 min prior to 
injection being given
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•	 Intravitreal	 injection	 preparation	 –	 Intravitreal	
bevacizumab is drawn into an insulin syringe usually 
1.25 mg in 0.05 ml with the aim of giving half (0.625 mg 
in 0.025 ml) under aseptic condition
•	 The	bevacizumab	 injection	 for	 each	patient	 is	 usually	
prepared and withdrawn into the insulin syringes from 
the bevacizumab vial by a scrubbed assistant to prevent 
any form of contamination or infection if more than one 
patient is to be injected
•	 A	new	27‑G	needle	is	then	placed	on	the	tip	of	the	insulin	
syringe with the bevacizumab injection placed on the 
sterile trolley for each patient
•	 If	 bilateral	 intravitreal	 bevacizumab	 injections	 are	 to	
be given, a separate tray with different instruments is 
prepared for each eye
•	 The	periocular	area	is	cleaned	with	a	sterile	5%	povidone	
iodine-soaked gauze mounted on a cleaning forceps in an 




bevacizumab, cleaning and draping is done individually 





prevent any sudden movements [Figure 2]
•	 The	 site	 of	 injection	 is	 identified;	 usually	 in	 the	
inferotemporal quadrant but may vary depending on the 
quadrant with better scleral exposure for measurement
•	 A	pair	of	calipers	is	used	to	measure	the	site	of	injection	
usually 1.5 mm from the limbus to avoid the lens being 
damaged; the distance may vary in bigger babies [Table 1][30,31]
•	 The	surgeon	then	expresses	the	excess	drug	to	have	0.625	
mg in 0.025 ml in the syringe
•	 The	27‑G	needle	 is	 introduced	 into	 the	eye	at	1.5	mm	
from the limbus toward the direction of the optic nerve 
head bevel up [Figure 2]
•	 0.625	mg	 in	 0.025	ml	 of	 bevacizumab	 is	 injected	
intravitreally
•	 The	needle	 is	 then	gently	withdrawn	 and	 a	 cotton	 tip	
soaked in povidone iodine is placed over the entry point 
of the injection [Figure 2]
•	 The	intraocular	pressure	is	checked	digitally;	if	the	globe	
is	tense,	a	gentle	paracentesis	may	be	done	with	a	27‑G	




with a sterile gauze and removed
Figure 2: (a) Cleaning, draping, speculum placement, and head stabilization by the assistant; (b) preinjection antibiotic instillation; (c) calipers to measure 
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Figure 3: Anatomical landmarks for sclerotomy in the pediatric population






for apnea with a close watch on the vital signs and oxygen 
saturation depending on neonates’ health
•	 Hourly	instillation	of	moxifloxacin	eye	drops	for	the	first	
24 h
•	 Neonates	 are	 reviewed	at	 the	neonatal	 care	unit	 about	
6 h postoperatively; the eye is examined for any signs of 
undue	inflammation	and	the	state	of	health	of	the	neonate.	
Intraocular pressure is tested digitally or with Icare 
Tonometer in suspicious cases. Most times, intraocular 
pressure is low following paracentesis
•	 Neonates	are	also	reviewed	24	h	postinjection	with	careful	
examination of the anterior segment looking for corneal 
edema,	anterior	chamber	 reaction,	or	fibrin.	Binocular	
indirect ophthalmoscopy is done to exclude vitreous 
inflammation	and	endophthalmitis
•	 Topical	antibiotic	is	continued	for	a	week	and	examined	
again 1 week postinjection
•	 Other	management	is	continued	by	the	neonatologists.
Follow‑up visits
•	 Patients	 are	 reviewed	1	week	postinjection	 for	 dilated	




then monthly until regression and maturation of retinal 
vessels
•	 Patients	will	then	be	referred	for	review	by	the	pediatric	





Ibadan, in 2017. We have screened more than 250 neonates, out 
of which we have treated 10 neonates with laser photocoagulation 
and given intravitreal bevacizumab to 13 eyes.[32]
The most important consideration is the accurate localization 
of the injection site in premature babies.
The surgeon must be conversant with the following anatomical 
landmarks [Figure 3].[30] The peculiarities of the premature 
and neonatal eye should be considered before administration 
of intravitreal injections.
Based	 on	 these	 peculiarities,	Table 1 is proposed, which 
indicates that a distance of 1.5 mm should be used for babies 
below 6 months of age.
Previous	studies	suggest	that	the	site	of	injection	should	avoid	
damage to the ciliary body, retina and the lens in babies below 
6 months of age. An average of 1.5 mm distance from the 
limbus is advised. This will avoid damage to the retina, ciliary 
body, and the lens.[30]
The standard precautions taken for adult patients need to 
be followed as the development of intraocular infection is 
devastating for a neonate and may lead to the loss of the eye 
more rapidly.
The intravitreal injection is given in the operating theater of the 
University	College	Hospital,	Ibadan,	under	aseptic	conditions.	
We also use an operating microscope to accurately localize 
the	site	of	injection.	Povidone	iodine	5%	is	used	for	both	the	
eyelid skin and the conjunctiva sac and irrigated subsequently 
to avoid sensitivity.
A	neonatal	 speculum	is	used	and	 is	 specific	because	of	 the	
size of the eye.
Topical anesthesia with tetracaine hydrochloride is used with 
caution to avoid cornea edema.[33]
The calipers must be accurate, and the adjustment must be 
checked before use.
A	27‑G	needle	with	a	1‑ml	syringe	is	advised.	A	little	more	
than	 the	 required	dose	of	anti‑VEGF	 is	withdrawn	 into	 the	
syringe. Thereafter, air in the syringe and the injecting needle 
is carefully expelled until a drop of the drug is noticed at the 
tip of the needle, while simultaneously ensuring the mark on 
the insulin syringe is set at 0.025 ml.
After injecting the drug, a sterile cotton bud is placed over the 
site	to	prevent	reflux	of	the	drug	and	vitreous	incarceration.
Paracentesis	is	done	after	the	injection	to	reduce	the	intraocular	
pressure. The anterior chamber of the neonate is shallow; 
therefore,	the	paracentesis	with	a	27‑G	or	30‑G	needle	is	done	
by entering the anterior chamber perpendicularly and parallel 
to the iris. This will avoid damage to the iris or lens. It is also 
better not to dilate the pupil before the procedure. This will 
protect the lens.
Nigerian Journal of Medicine ¦ Volume 29 ¦ Issue 3 ¦ July-September 2020464
Babalola, et al.: Method of administration of AntiVEGF for ROP  
Postoperative	use	of	 topical	 antibiotics	 is	 advised.	The	eye	
should not be padded to prevent amblyopia.
Babies	are	reviewed	6	hours	and	24	hours	after	the	injection	
for signs of endophthalmitis.
Pediatric	ophthalmology	follow	up	is	mandatory	to	detect	other	
ocular		complications	of	prematurity.	Pediatricians	also	need	
to follow up with the babies for systemic complications.[34,35]
conclusIon
Intravitreal	 anti‑VEGF	may	 prevent	 avoidable	 blindness	
in	 babies	with	ROP.	However,	 the	 adverse	 effects	 of	 the	
procedure can be devastating. Appropriate techniques and the 
guidelines given in this study should be considered to minimize 
complications.
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